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Cardiomyopathies with intracellular inclusions are a distinct subset of cardiomyopathies whereas 
basophilic degeneration (BD) of the heart describes inclusions in cardiomyocytes of the aging 
heart, which have not yet been related to a specific disease condition or to a distinct type of protein 
inclusion. To address the question whether BD represents a specific pathological feature and whether 
it is linked to a distinct disease condition we studied 62 autopsy cases. BD inclusions exhibited an 
immunohistochemical staining pattern related to glycosylated, δ- or η-secretase-derived N-terminal 
cleavage products of the amyloid precursor protein (sAPPδ/η) or shorter fragments of sAPPη. BD 
aggregates were found in the myocardium of both ventricles and atria with highest amounts in the atria 
and lowest in the interventricular septum. The frequency of BD-lesions correlated with age, degree 
of myocardial fibrosis in individuals with arterial hypertension, and the severity of cerebral amyloid 
angiopathy (CAA). The intracytoplasmic deposition of N-terminal sAPPδ/η fragments in BD indicates 
a specific inclusion body pathology related to APP metabolism. The correlation with the severity of 
CAA, which is related to the APP-derived amyloid β-protein, supports this point of view and suggests a 
possible link between myocardial and cerebrovascular APP-related lesions.
Cardiomyopathies with intracellular inclusions are a distinct subset of cardiomyopathies. Major forms are the 
desmin-related myopathies in skeletal and heart muscle1 or the myocardial affection in inclusion body myo-
pathy with early-onset Paget disease with or without frontotemporal dementia (IBMPFD)2. In addition to 
disease-related cardiomyocyte inclusions basophilic degeneration of the heart (BD) represents age-related baso-
philic inclusions in cardiac myocytes3,4. The inclusions were originally described based on hematoxylin and eosin 
(H&E)-stained sections as “a small, round, oval, or irregular pale blue area inside of a single muscle cell”4. These 
lesions are positive in the periodic acid-Schiff reaction staining (PAS)5,6 and polyglucosan immunohistochem-
istry7 raising the idea that BD consists of glycogen metabolism by-products5,7. At the electron microscopic level 
BD consists of randomly distributed fibrils rimmed by myofibrils5. However, a distinct pathological role of BD 
has not yet been identified.
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The amyloid precursor protein (APP) is known as precursor protein for the Alzheimer’s disease (AD)-related 
amyloid β-protein (Aβ)8. Aβ is released after β- and γ-secretase cleavage9 and is considered to be a key protein 
in the pathogenesis of AD10–12. The deposition of Aβ in the wall of leptomeningeal and cerebral blood vessels 
is the hallmark lesion of cerebral amyloid angiopathy (CAA)13, which develops not only linked to AD-related 
Aβ-production as shown in APP-transgenic mice14 but also in spontaneous hypertensive, stroke-prone rats 
(SHRSP)15,16 in the absence of amyloid plaques indicating a potential association between CAA and arte-
rial hypertension. Moreover, δ- and η-secretase cleavage has been described cutting APP N-terminal to the 
β-secretase cleavage site releasing C-terminal fragments called CTFδ (by δ-secretase cleavage) and CTFη (by 
η-secretase cleavage) and N-terminal fragments called sAPPδ and sAPPη17,18. Aη is generated in a second cleav-
age step cutting CTFη by α- or β-secretase into Aη-α/β and CTFα/β18 (Fig. 1). APP-like proteins (APLPs) are 
homologues of APP lacking the Aβ region and are termed APLP1 and APLP219–21. The role of APP, its cleavage 
products or its homologues APLP1 or APLP2 in heart pathology is not fully understood although it is known that 
APP and APLP2 are expressed in cardiomyocytes19 and some authors found that Aβ may play a role for cardiomy-
ocyte degeneration in patients with heart failure22. In myofibrillar myopathy of the skeletal muscle accumulation 
of APP-positive material has been reported23. In so doing, the question arises whether Aβ/APP metabolism plays 
a role for the development of cardiac pathological lesions and if so whether they are related to AD or CAA.
To address this question and to clarify the role of BD as an age-related lesion of the heart we studied 62 autopsy 
cases. Our results showed that BD-lesions consist of N-terminal APP-fragments and were associated with the 
severity of CAA and with myocardial fibrosis in individuals with arterial hypertension.
Results
sAPPδ373/η epitopes are exhibited in p62/SQSTM1-, ubiquitin-, and PAS-positive BD-inclusions 
of cardiomyocytes. To clarify the nature of BD-lesions we stained cross sections through the myocardium 
of the left ventricle with H&E, antibodies against p62/SQSTM1 and with the PAS-staining from all 62 cases 
included in this study (Table 1, Suppl. Table 1). PAS-positive BD-lesions in cardiomyocytes were found to express 
p62/SQSTM1 as shown in subsequent sections (Fig. 2A,C,F,H,J,L,M,O). To clarify whether other markers for an 
impaired proteasomal degradation of proteins confirm this finding and to screen for proteins that could be sub-
ject of impaired proteasomal degradation we screened cases No. 1, 15, 17, 50, 53, 56 and 58 (see Suppl. Table 1) 
with the antibodies listed in Suppl. Table 2. The pattern seen for BD-lesions was reproducible in all seven inves-
tigated cases. Antibodies against ubiquitin and ubiquilin were used to confirm an impaired proteasomal degra-
dation, antibodies against abnormal τ-protein, α-synuclein, phosphorylated transactive response DNA-binding 
protein pTDP43, and Aβ/APP to identify potential target proteins that can theoretically accumulate in the cell, 
and antibodies against muscle-derived proteins to address the question whether BD-lesions represent a disorder 
of the cardiomuscular intermediary filaments. The p62/SQSTM1-positive BD-lesions were immunopositive for 
ubiquitin, ubiquilin, and N-terminal epitopes of APP (Fig. 2B,D,E,H,I, Suppl. Table 2). The M- and D-epitope 
representing the Aη-region of APP as well as the Aβ fragment were not detected (Fig. 2G,H,K,L, Table 1). An 
antibody directed against APLP2 did not stain the p62/SQSTM1-positive BD inclusions as demonstrated by dou-
ble label immunohistochemistry (Fig. 2K,O). It is essential to note that APP is physiologically expressed in the 
cytoplasm of cardiomyocytes. Lipofuscin granules were also stained with the anti-APP (except for antibodies 
targeting specifically Aβ epitopes; Fig. 3A–E) and anti-APLP2 antibodies (Fig. 3F,G). Actin, desmin, myosin 
Figure 1. Schematic representation of APP cleavage by α-, β-, γ-, δ- and η-secretase and generation of sAPPδ 
and sAPPη. The δ-secretase can thereby cut at the amino acid position 373 as well as at position 585. As such, 
δ-secretase cleavage can produce a longer N-terminal fragment that is detectable with antibodies against the  
D- and M-epitope sAPPδ585 and fragments that do not contain these epitopes, i.e. sAPPδ37317. sAPPδ373 and sAPPη 
can be detected with antibodies against the N-terminus of APP (22C11, 9023) but not with antibodies detecting 
APP C-terminal to the δ373 or η-secretase cleavage site. sAPPδ/η contain glycosylation sites possibly explaining 
the detection of its glycosylated form stained by the PAS-method. The antibodies used for APP-staining do not 
differentiate between sAPPδ373, sAPPη and shorter N-terminal fragments of APP.
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and filamin C were not detected in BD-lesions (Suppl. Table 2). Accordingly, the cytoplasmic BD-inclusions in 
cardiomyocytes consisted of sAPPδ373, sAPPη or shorter N-terminal fragments of APP, which were PAS-positive 
(presumably glycosylated) and colocalized with ubiquitin, ubiquilin and p62/SQSTM1-positive material. TDP43, 
Aβ, abnormal phosphorylated τ-protein, desmin and other proteins listed in Suppl. Table 2 were not found in the 
aggregates. To confirm the presence of N-terminal APP-epitopes in BD-lesions we also stained the left ventricle 
myocardial sections of the rest of the 62 cases with anti-APP (22C11) which is directed against an N-terminal 
epitope of APP. In all cases with BD-lesions detected with anti-p62/SQSTM1 and the PAS-staining we also saw 
anti-APP-positive BD-lesions further confirming that BD-lesions represent aggregates of N-terminal APP-
fragments. Cases free of BD-lesions in the PAS and anti-p62/SQSTM1-staining did not exhibit anti-APP-positive 
cardiomyocyte inclusions.
To document that the BD-lesions identified here by histological criteria fit with the ultrastructural pattern of 
BD5 we performed electron microscopy in case No. 53 (Suppl. Table 1). The BD-lesions were identified according 
to its structural appearance in methylene blue-stained semithin sections as lesions consisting of amorphous mate-
rial with a rim of myofibrils in the periphery (Fig. 4A,B)5. In ultrathin sections electron microscopy confirmed 
that BD-lesions contained fibrillar material (Fig. 4C,D). This material was not coated by a membrane and sharply 
bordered from adjacent myofibrils. Only few myofibrils and organelles were seen between the fibrillar aggregates 
(Fig. 4C). Lipofuscin-like material was not observed inside the BD-lesion (Fig. 4C,D).
Distribution of BD-inclusions in the heart. To document the anatomical distribution of BD-lesions 
throughout the heart we embedded gross sections (6,5 × 4,8 cm of size) of the apex, left and right ventricle includ-
ing the intraventricular septum, and the atria of 8 cases in paraffin, stained paraffin sections with hematoxylin 
and eosin, and immunostained them with anti-p62/SQSTM1 antibodies. After demonstration that the immu-
nostaining for p62/SQSTM1 detects BD-lesions in the heart (Fig. 2A–C) and that it provides an easy detection 
of the BD-lesions (Fig. 5A–D) we used anti-p62/SQSTM1 immunohistochemistry for assessing the frequency of 
BD-lesions in a given part of the heart. The gross sections of the heart covered transverse sections of the entire 
heart a) at the level of the atria including both atria and the septum intraatriale and b) at the ventricular level 
covering both ventricles including the intraventricular septum and papillary muscles, and c) at the level of the 
apex of the heart. Using these sections, p62/SQSTM1-positive BD-inclusions in cardiomyocytes were observed 
in both ventricles and atria (Fig. 5A–D). The highest number of affected cardiomyocytes was seen in the atria and 
the lowest in the intraventricular septum (Fig. 5E). The number of atrial BD-inclusions was generally higher than 
that in ventricular areas (Wilcoxon rank sum test (single sided): p < 0.05). BD-inclusions were mainly found in 
the myocardial parenchyma outside the conduction system although the muscle fibers of the conduction system 
were not spared.
In the available samples of the quadriceps femoris muscle and/ or the diaphragm (n = 30), we wanted to clar-
ify whether BD-lesions were limited to the heart or were also prevalent in the skeletal muscle as well. Using the 
Data available 
in n cases
Age in years (mean/range) 57,5/0–85 62
Gender (M/F) 45/17 62
Atrial fibrillation (y/n) 9/42 51
Arterial hypertension (y/n) 26/36 62
Myocardial infarction (y/n) 9/53 62
Heart weight/g (mean/range) 410/8–850 62
Degree of cardiac fibrosis (mean/range) 1.56/0–3 62
Degree of hypertension-related cardiac fibrosis (mean/range) 0,694/0–3 62
p62-positive BD inclusions/mm² (left ventricle) (mean/range) 0.084/0–0.804 62
Diabetes mellitus (y/n) 9/53 62
Hyperlipoproteinemia (y/n) 10/28 38
Obesity (y/n) 15/23 38
Intracerebral hemorrhage (y/n) 8/54 62
Cerebral infarction (y/n) 16/46 62
Athersclerosis (mean/range) 31,25%/0–100% 59
Stage of SVD (mean/range) 1.6/0–3 62
Severity grade of CAA (mean/range) 0,23/0–2 62
Aβ-phase (MTL) (mean/range) 0.65/0–4 62
Braak NFT-stage (mean/range) 1.18/0-4 62
CERAD-score (mean/range) 0.13/0–2 62
NIA-AA degree of AD (mean/range) 0.39/0–2 62
Table 1. Distribution of age, gender, clinical and pathological diagnoses. Numbers of cases, age-spectrum, 
cardiac and AD-related pathologies and parameters, arterial hypertension, diabetes mellitus, atherosclerosis, 
cerebral small vessels disease (SVD), CAA, and heart weights: Mean values and ranges. The list of the individual 
cases is provided in Supplementary Table 1.
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Figure 2. Ubiquitinated and glycosylated p62/SQSTM1-immunopositive BD-inclusions exhibiting N-terminal 
epitopes of APP in cardiomyocytes in cross sections through the left ventricle wall. (A) BD-inclusion (arrows) 
stained with the PAS histochemical staining method in a cardiomyocyte of the left ventricular myocardium 
in case No. 53. (B) Subsequent section of the BD-inclusion of case No. 53 depicted in A immunostained with 
anti-APP (22C11) antibodies against the N-terminus of APP (arrows). Note that neighboring cardiomyocytes 
exhibit a physiological APP expression in the cytoplasm, focally associated with lipofuscin granules. (C) p62/
SQSTM1- immunohistochemistry showed in another subsequent section of the BD-inclusion of case No. 53 
depicted in (A,B) the presence of p62/SQSTM1 (arrows). The aggregates exhibited an amorphous structure 
and were sharply delineated. (D) The section shown in C was also stained for ubiquilin by double label 
immunofluorescence, which was colocalizing with p62/SQSTM1 in the BD-lesion (arrows). (E–H) Triple 
label immunofluorescence of a BD-lesion in the myocardium of the left ventricle of case No. 17. The BD-
lesion was stained with anti-APP (22C11) detecting the N-terminus of APP (arrow in E,H) and p62/SQSTM1 
(arrow in F,H) whereas the antibody against the D-epitope of the Aη-region did not detect this lesion (arrow 
in G,H). (I–L) Triple label immunofluorescence of a BD-lesion in case No. 50 shows expression of ubiquitin 
(arrow in I,L) and p62/SQSTM1 (arrow in J,L) but no expression of Aβ detected with the antibody (3552)44 
(arrow in K,L). (M–O) Double label immunofluorescence of a BD-lesion in the left ventricular myocardium 
of case No. 56 showed a p62/SQSTM1-positive BD inclusion (arrowhead in M,O) which was not visible with 
the antibody against APLP2 (arrowhead in N,O) whereas the cardiomyocytes showed a mild physiological 
www.nature.com/scientificreports/
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PAS and anti-p62/SQSTM1-stainings we did not observe BD-lesions in the quadriceps femoris muscle or in the 
diaphragm of these individuals.
Prevalence of cardiac BD-inclusions with age. To study the frequency of BD-lesions in the heart we 
chose the left ventricle because previous studies reported the highest scores for BD-lesions in the left ventricle6 
and because tissue blocks from left ventricle cross sections were available in all cases included in this study. 
p62/SQSTM1-positive BD-inclusions bodies were observed in left ventricle samples of individuals ranging from 
35–85 years of age; patients younger than 35 (n = 4) did not exhibit p62/SQSTM1-positive BD inclusions. Five 
out of 54 cases between 35–78 years of age did not exhibit BD-inclusions in cardiomyocytes (Suppl. Table 1). The 
frequency of p62/SQSTM1-immunopositive BD-inclusions per mm² left ventricle section increased slightly with 
age (Linear regression analysis: R² = 0.074, β = 0.273, p = 0.023; Fig. 6A, Table 2).
Association of cardiac BD-inclusions with cardiac fibrosis in hypertensive individuals, and cere-
bral amyloid angiopathy (CAA). To clarify whether BD is related to a cardiovascular disease or risk factor 
we studied its association with arterial hypertension, myocardial infarction, atrial fibrillation, cardiac fibrosis, 
heart weight, diabetes mellitus, hyperlipoproteinemia, obesity, cerebral hemorrhage, cerebral infarction, cerebral 
small vessel disease, atherosclerosis of the circle of Willis, and CAA by using linear regression analysis with model 
terms including one or more independent variables. The number of p62/SQSTM1-positive BD-inclusions/mm² 
in the left ventricle was associated with the degree of myocardial fibrosis (Linear regression analysis – myocardial 
fibrosis: R² = 0.073, β = 0.270, p = 0.033, Table 2). This association was not seen after controlling the model term 
for age and gender (Linear regression analysis: p = 0.203, Table 2). When focusing on the degree of myocardial 
fibrosis in individuals with arterial hypertension and including non-hypertensive cases as controls BD was asso-
ciated with the degree of myocardial fibrosis in hypertensive individuals (Fig. 6B; Linear regression analysis: 
R² = 0.11, β = 0.332, p = 0.008, Table 2). After controlling the model term for a) age and gender (Linear regression 
analysis: β = 0.302, p = 0.032; R² = 0.163, Table 2), or b) myocardial infarction, and heart weight (Linear regres-
sion analysis: β = 0.329, p = 0.009; R² = 0.156, Table 2) the R² values of the model increased. Morphologically, 
p62/SQSTM1-positive BD-inclusions were found close to areas of fibrosis.
The severity degree of CAA24 was associated with the frequency of left ventricular p62/SQSTM1-positive 
BD-inclusions (Fig. 6C; Linear regression analysis: R² = 0.116, β = 0.340, p = 0.007, Table 2). This association was 
also seen in a model term controlled for myocardial infarction, degree of myocardial fibrosis, and heart weight 
(Linear regression analysis: R² = 0.166, β = 0.337, p = 0.006, Table 2) as well as in a model controlled for age 
and gender (Linear regression analysis: R² = 0.16, β = 0.273, p = 0.035, Table 2). Interestingly, the effects of CAA 
severity and the degree of myocardial fibrosis in hypertensive individuals showed an independent influence on 
the frequency of p62/SQSTM1-positive BD-inclusions increasing the R² of the model term to R² = 0.267 when 
tested in one model term with CAA severity, degree of myocardial fibrosis in hypertensive individuals as inde-
pendent variables controlled for myocardial infarction and heart weight in one model term (Linear regression 
analysis: R² = 0.267; CAA severity β = 0.339, p = 0.005; degree of myocardial fibrosis in hypertensive individuals 
β = 0.333, p = 0.005, Table 2) as well as when controlled for age and gender in the second (Linear regression 
analysis: R² = 0.26; CAA severity β = 0.334, p = 0.008; degree of myocardial fibrosis in hypertensive individuals 
β = 0.367, p = 0.007, Table 2).
No associations of the frequencies of BD-inclusions of the left ventricle were seen with (a) the stage of cerebral 
small vessel disease distribution (p = 0.545)25, (b) the percentage of vessels of the circle of Willis being macroscop-
ically affected by atherosclerosis (p = 0.161)26, (c) the presence of myocardial infarction (p = 0.922), (d) presence 
of atrial fibrillation (p = 0.055), (e) arterial hypertension (p = 0.065), (f) diabetes mellitus (p = 0.652), (g) obesity 
(p = 0.404), (h) hyperlipoproteinemia (p = 0.488), and (i) heart weight (p = 0.094) as observed by binary logistic 
and linear regression models (Table 2).
No association of cardiac BD-inclusions with AD pathology. To clarify whether p62/SQSTM1- 
positive BD-inclusions in cardiomyocytes exhibiting N-terminal epitopes of APP are related to AD-pathology 
linear regression analysis was calculated for the frequency of cardiomyocytes with p62/SQSTM1-positive 
BD-inclusions of the left ventricle as independent variable and the phases of Aβ plaque pathology in the medial 
temporal lobe (MTL)27, the Braak-neurofibrillary tangle (NFT) stages28, the score of neuritic plaque pathol-
ogy as recommended by the Consortium to establish a registry for AD (=CERAD-score)29, and the degree of 
AD-pathology according to the National Institute of Aging-Alzheimer’s Association recommendations30 as 
respective dependent variables. No association was found (p ≥ 0.072) (Table 2).
Discussion
Here, we show that inclusions in cardiomyocytes known as BD with the typical histopathological and ultrastruc-
tural pattern are detectable with antibodies directed against the N-terminus of APP. This accumulation of APP 
cleavage products is associated with the severity of CAA in leptomeningeal and cortical blood vessels. CAA is 
histopathologically characterized by the deposition of Aβ, which is another cleavage product of APP (Fig. 1A) 
and represents a cerebral vessel disorder known as the 2nd most frequent cause of hemorrhage in the elderly brain 
after hypertension-related bleedings31–33. This association as well as the involvement of APP in both pathologies 
cytoplasmic staining of APLP2. (P–R) Negative controls (myocardium of the left ventricle from case No. 17) for 
immunofluorescence stainings were performed by omitting primary antibodies (only secondary antibodies/
detection agents): Carbocyanin-2 (Cy2)-conjugated streptavidin (P) Cy5-conjugated anti-mouse IgG (Q) and 
Cy3-conjugated anti-rabbit IgG secondary antibodies (R). Positive controls are depicted in Suppl. Fig. 1.
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Figure 3. Physiological expression of APP and APLP2 in heart muscle cells of the left ventricle. (A) With an 
antibody directed against the N-terminus of APP there was a mild cytoplasmic staining in all cardiomyocytes 
of a left ventricle sample from case No. 15 exhibiting longitudinal-skewed cut muscle fibers. One BD lesion 
was seen (arrow) (B) In these cells lipofuscin particles (black arrowheads) were also stained as seen at the 
higher magnification level. The BD-inclusion (arrow) was morphologically different from the lipofuscin 
particles because it was bigger and showed a homogenous mass of strongly APP-positive material in the 
mildly APP expressing muscle cells. The nuclei of the cardiomyocytes were not stained and serve as intrinsic 
negative control for this staining (red arrowheads). (C) The Aη-D-epitope of APP was also expressed in all 
cardiomyocytes, here shown in a sample of the left ventricle myocardium of case No. 15. The muscle fibers were 
cut transversally. (D) At higher magnification level lipofuscin particles were also stained with the antibody 
against the Aη-D-Epitope (black arrowheads). BD-lesions were not seen with this antibody. The nuclei of the 
cardiomyocytes were not stained and served as intrinsic negative control for this staining (red arrowheads). 
(E,F) The Aβ epitope of APP was only faintly stained in cardiomyocytes of the left ventricle myocardium of 
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may point to a possible molecular link between both pathologies. However, no significant association was seen 
with AD-related amyloid plaque pathology as represented by the amyloid plaque phases in the MTL27 as well 
as with neuritic plaque pathology as assessed by the CERAD-score for neuritic plaque pathology29 and with 
NFT-pathology assessed by the Braak NFT-stages28.
In the BD-lesions, the aggregated N-terminal APP fragments colocalize ubiquitin, p62/SQSTM1, and 
PAS-positivity, presumably indicative for the presence of glycosylated proteins such as APP that could be ubiq-
uitinated and linked to p62/SQSTM1, as demonstrated by triple label immunofluorescence and by assessing sub-
sequent sections. To classify these APP fragments, we used antibodies detecting the Aβ-region of APP as well as 
epitopes N-terminal to the β-secretase cleavage site of APP but C-terminal to the δ373- and η-secretase cleavage 
site (D- and M-epitopes of APP)18 (Fig. 1). Only the 22C11 and the 9023 APP antibodies – both detecting sAP-
Pδ/η – stained cytoplasmic inclusion bodies whereas all other antibodies, including those against APP-epitopes 
C-terminal to its δ and η-cleavage sites, remained negative (Fig. 1). Since the 22C11 antibody crossreacts with 
APLP2 we excluded APLP2 as possible component in the BD-lesions by double label immunofluorescence 
detecting p62/SQSTM1 and APLP2. Accordingly, the material that accumulates in BD-lesions and colocalized 
PAS-positivity, p62/SQSTM1, and ubiquitin appears to represent aggregates of sAPPη, sAPPδ373, or another 
N-terminal APP fragment with its C-terminus N-terminal to the η-secretase cleavage site (Fig. 1).
BD cytoplasmic inclusion bodies of heart muscle cells in the majority of elderly individuals are different 
from other cardiomyopathies including those with inclusions containing mutant proteins such as desmin or 
valosin-containing protein. Nuclear inclusions and similar aggregates in the skeletal muscle were not observed 
as it is expected in IBMPFD2 or desmin-related myopathies1. The fact that BD lesions were not associated with 
the clinical diagnosis “glycogenosis” and that they contained aggregates of sAPPδ/η argue against a disorder of 
glycogen metabolism as considered by some authors5,7. An association with diabetes mellitus, obesity and hyper-
lipoproteinemia was not found in our cases. Moreover, the fact that presenilin 1/2 (i.e. the active center of the 
γ-secretase34) mutations can cause cardiomyopathies35 and that Aβ can cause degeneration of cardiomyocytes22 
may further argue in favor of a critical function of APP and/or its cleavage products in the heart. The presence 
of APP in the BD-lesions also argues against impaired autophagy as primary cause of BD because other protein 
aggregation disorders that accumulate p62/SQSTM1-positive material can be driven by specific mutations of the 
accumulating protein such as mutations in the α-synuclein gene in Parkinson’s disease36 or in the TDP43 gene 
(TARDBP) in amyotrophic lateral sclerosis (ALS)37. As such, it is tempting to speculate that APP and the accu-
mulation of its N-terminal fragments is critically involved in BD-related cardiomyocyte degeneration, probably 
similar to the role of α-synuclein in sporadic Parkinson’s disease or TDP43 in sporadic ALS.
p62/SQSTM1-positive sAPPδ/η aggregates in cardiomyocytes representing BD are associated with age con-
firming previous studies on BD3,5–7 and with myocardial fibrosis in the left ventricle of hypertensive individuals. 
A significant association with heart weight, myocardial infarction, arterial hypertension alone or atrial fibrillation 
could not be seen. Previous studies on BD already discussed a frequent occurrence of these lesions in cases with 
cardiovascular diseases3,6. Some animal models with autophagic-lysosomal inhibition leading to increased p62/
SQSTM1-levels show hypertension38 or cardiomyopathy39,40 further arguing in favor of a potential link between 
the accumulation of p62/SQSTM1-positive protein aggregates in cardiomyocytes with BD and hypertension or 
cardiomyocyte degeneration.
Recently, it was shown that spontaneously hypertensive stroke-prone rats (SHRSP) develop CAA15,16. This 
finding supports the association between a cardiac pathology which is related to arterial hypertension and CAA. 
Another, argument for a link between hypertension-related cardiac pathology and CAA is the finding of Gerth et al. 
that a distinct group of CAA cases based upon the parenchymal/vascular distribution pattern of modified Aβ 
forms was associated with arterial hypertension41. These results from other studies further support the hypothesis 
that hypertension-related lesions of the heart and CAA are linked.
The distribution of BD-lesions in all parts of the heart without specific affection of the conduction system con-
firms earlier studies3,6 and indicates that this pathology may affect the function of the entire heart. Earlier studies 
based upon H&E-stained tissue samples showed slight differences in the distribution over the heart. In these 
H&E-based studies, the most BD-lesions were found in the septum and the ventricles whereas they appeared less 
abundant in the atria3,6. Since we used immunohistochemistry for the specific detection of the lesions our find-
ings may be less biased than the studies from 19353 and 19556 because of superior methodology for the detection 
of the BD-lesions, which is now available with highly specific immunohistochemical markers such as anti-p62/
SQSTM1 and anti-APP antibodies. This enables us now to define BD-lesions as p62/SQSTM1-positive aggregates 
of sAPPδ/η and allows more precise correlation analyses with disorders potentially related with these lesions.
In summary, we describe BD-lesions to represent inclusions of sAPPδ/η aggregates in cardiomyocytes. BD 
appears, thereby, to represent an age-related protein aggregation pathology in the heart associated with CAA and 
myocardial fibrosis in individuals with arterial hypertension. Since APP is involved in both CAA and BD a molec-
ular link appears possible as well as a link with hypertension-associated cardiomyocyte alterations.
case No. 58 using an antibody raised against Aβ1–17. No BD-lesions could be seen. Lipofuscin was not stained as 
well. The nuclei of the cardiomyocytes were not stained and served as intrinsic negative control for this staining 
(red arrowheads). The muscle fibers were cut transversally. (G) APLP2 was expressed in the cytoplasm of all 
cardiomyocytes of the left ventricular myocardium of case No. 1 exhibiting muscle fibers in longitudinal-skewed 
orientation. (H) At the higher magnification level lipofuscin particles (black arrowheads) were stained with this 
antibody as well. BD-lesions could not be detected with this antibody. The nuclei of the cardiomyocytes were 
not stained and served as intrinsic negative control for this staining (red arrowheads). (I,J) Negative controls by 
omitting the primary antibodies for biotinylated anti-mouse IgG (I) and anti-rabbit IgG secondary antibodies 
(J) were performed on left ventricular myocardium of case No. 44. Positive controls are shown in Suppl. Fig. 1.
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It will be also important to be aware of BD in the pathological differential diagnosis of inclusion body cardio-
myopathies with p62/SQSTM1- or ubiquitin-positive inclusions.
Methods
All methods have been performed in accordance with the relevant guidelines and regulations.
Pathology. Heart and brain tissue of 62 autopsy cases was studied (Table 1, Suppl. Table 1). Quadriceps 
femoris muscle and/or diaphragm were available for 30 of these cases. The heart weight was obtained at autopsy.
The age-range of the sample was 0–85 years. Cases with and without heart and/or brain disorders were 
included (Table 1, Suppl. Table 1). The autopsy tissue has been collected by the Ulm University Brain Bank at the 
Institute of Pathology with approval of the local Ethics Committee (Decision-No. 378/13). The autopsies were 
performed with informed consent of the next in kin. Cause of death included cancer (n = 4), cardiovascular dis-
ease (n = 28), respiratory failure (n = 18), neurological reasons (n = 8), multiple organ dysfunction (n = 1), and 
infectious diseases (n = 3). Inclusion criteria were the availability of autopsy tissue from brain and heart of a given 
case. Exclusion criteria were spongiform encephalopathies, tuberculosis, HIV, hepatitis B and C infections. The 
reason for excluding cases with these infectious disorders was the safety in the research laboratory.
Tissue samples were formalin fixed and embedded in paraffin. Left ventricle samples covering cross-sections 
through the myocardium of all hearts were stained. Brain pathology was studied as previously published42. 
5 µm thick sections from all cases were cut and stained with the hematoxylin and eosin, Masson-Goldner, and 
Figure 4. (A) Structural analysis of cytoplasmic BD-inclusions in a semithin section of the left ventricular 
myocardium of case No. 53 stained with methylene blue. The inclusion body (arrow) was located intracellular in 
the sarcoplasm of a transversally cut cardiomyocyte and its morphological appearance identified this inclusion 
as BD-inclusion as described previously5. Cardiomyocytes were surrounded by cardiac fibrosis consisting 
of collagen fiber tissue. (B) Enlarged section of (A) The inclusion body was sharply delineated (arrows) 
and contained aggregates of amorphous material. The boxed area indicates the part of the cardiomyocyte 
depicted in C at the ultrastructural level. (C,D) The BD-inclusion was also analyzed in ultrathin sections by 
electron microscopy. The aggregates were not membrane-coated and sharply demarcated from surrounding 
myofibrils (C: arrows). Between the aggregates only few myofibrils (C: mf) and no preserved cell organelles 
(D) could be seen. The aggregated material exhibited a fibrillar pattern at the higher magnification level (D). 
The cell membrane of the cardiomyocyte was intact (C: arrow heads) and surrounded by cardiac fibrosis. This 
ultrastructural pattern confirmed these lesions to represent BD.
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periodic-acid Schiff (PAS) staining techniques. Immunohistochemistry was performed with antibodies listed in 
Supplementary Table 2. All cases were thereby stained with antibodies against p62/SQSTM1 and the N-terminus 
of APP (22C11) whereas the other antibodies were only used in cases No. 1, 15, 17, 50, 53, 56 and 58 to illustrate 
the expression pattern of the BD-lesions with the antibodies listed in Suppl. Table 2. For visualization primary 
antibodies were either detected with Carbocyanin 2, Carbocyanin 3, or Carbocyanin 5-marked secondary anti-
bodies or with biotin-labeled secondary antibodies, avidin-biotin complex and diaminobencidine-HCl or the 
Figure 5. p62/SQSTM1-immunopositive BD inclusions were found in muscle cells of all parts of the heart 
of case No. 21 shown in transversal sections of the atrium, interventricular septum, and the left and right 
ventricles. (A) Two p62/SQSTM1-positive BD-inclusions are seen in this figure of the right ventricle (arrows). 
(B) Three BD-inclusions are marked with anti-p62/SQSTM1 in this image of the left ventricle (arrows). (C) 
The intraventricular septum image shows one BD-lesion (arrow). (D) The section of the atrium depicts five 
p62/SQSTM1-positive BD-lesions (arrows) indicating the high frequency of BD-lesions that could be detected 
in the atria by immunohistochemistry. The lesions were disseminated over the area of the atrial myocardium. 
(E) Assessment of the frequency of p62/SQSTM1-positive BD-inclusions in immunostained gross sections of 
the atria, ventricles and the intraventricular septum in cases No. 17, 21, 30, 33, 39, 44, 52, and 55 revealed the 
highest amount of inclusions in the atria and the lowest in the interventricular septum. The boxplot diagram 
shows the distribution of BD-inclusions/mm2 in the right and left ventricle, the interventricular septum and 
the atria (*statistical outliers, *significant at the 0.05 level (single sided Wilcoxon rank sum test), n = 8). The 
negative staining control showing only the staining with the secondary antibody while omitting the primary one 
is shown in Fig. 3 (I). The positive control for the p62/SQSTM1 antibody is depicted in Suppl. Fig. 1A.
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Figure 6. The frequency of p62/SQSTM1-immunopositive BD-inclusions/mm2 of the left ventricular 
myocardium was compared to age (A) the degree of myocardial fibrosis in hypertensive individuals (B) 
and CAA severity (C). (A) The frequency of inclusions increased very mildly in correlation with the age as 
demonstrated in a scatter diagram (Linear regression analysis: R² = 0.074; β = 0.273, p = 0.032, n = 62, Table 2) 
(black line = regression line). (B) An association of p62/SQSTM1-positive BD-inclusions of the left ventricle 
with the degree of myocardial fibrosis in hypertensive individuals is shown in this boxplot diagram (Linear 
regression analysis controlled for age and gender: R² = 0.163; β = 0.302, p = 0.032, n = 62, Table 2). (C) The 
boxplot diagram shows the association between the frequency of left ventricular BD-inclusions and the CAA 
severity (Linear regression analysis controlled for age and gender: R² = 0.16; β = 0.273, p = 0.035, n = 62, 
Table 2). (B,C) ° and *statistical outliers).
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DAKO-Real alkaline phosphatase/RED substrate kit (DAKO, Glostrup, Denmark). In the event that we com-
bined two mouse antibodies in a triple staining, the second primary mouse antibody was linked to biotiny-
lated Fab-fragments against mouse IgG prior to the incubation with the sample and Carbocyanin 2-conjugated 
streptavidin was used for visualization43. Positive and negative controls were carried out. Light and fluorescence 
microscopy was performed with a Leica DMLB microscope (Leica, Germany). Pictures were taken with Leica 
DFC 290 and DFC 7000 T digital cameras (Leica, Germany) and were processed for contrast and colocalization 
overlays with CorelPhotopaint XVI. In images of triple labelled sections, the red-orange Carbocyanin 3 signal 
was pseudo-coded in blue.
Heart pathology (infarcts, fibrosis, and conventional signs of cardiomyopathy), skeletal muscle pathology, 






















individuals Diabetes mellitus (y/n)
62 62 51 62 62 62 62 62 62
p62/SQSTM1-positive BD inclusions: 
binary logistic (*) and linear regression 
(only one independent variable)
β = 0.273; 
p = 0.032; 
R² = 0.074
p = 0.469* p = 0.055* p = 0.065* p = 0.922* p = 0.094
β = 0.270; 
p = 0.033; 
R² = 0.073
β = 0.332; 
p = 0.008; 
R² = 0.11
p = 0.652*
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for age 
and gender
n.d. n.d. n.d. n.d. n.d. n.d. p = 0.203
β = 0.302; 
p = 0.032; 
R² = 0.163
n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
myocardial infarction and heart weight
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.329; 
p = 0.009; 
R² = 0.156
n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for diabetes 
mellitus, obesity and atrial fibrillation
n.d. n.d. n.d. n.d. n.d. n.d. n.d. p = 0.17 n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for CAA 
severity
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.304; 
p = 0.004; 
R² = 0.233
n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
age, gender, and cardiac fibrosis in 
hypertensive individuals
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.367; 
p = 0.007; 
R² = 0.26
n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
myocardial infarction, heart weight, 
and cardiac fibrosis in hypertensive 
individuals
n.d. n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.333; 






























38 38 62 62 59 62 62 62 62 62 62
p62/SQSTM1-positive BD inclusions: 
binary logistic (*) and linear regression 
(only one independent variable)
p = 0.488* p = 0.404* p = 0.247* p = 0.181* p = 0.161 p = 0.545
β = 0.340; 
p = 0.007; 
R² = 0.116
p = 0.094 p = 0.166 p = 0.137 p = 0.072
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for age 
and gender
n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.273; 
p = 0.035; 
R² = 0.16
n.d. n.d. n.d. n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
myocardial infarction, degree of 
myocardial fibrosis and heart weight
n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.337; 
p = 0.006; 
R² = 0.166
n.d. n.d. n.d. n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for diabetes 
mellitus, arterial hypertension and 
atrial fibrillation
n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.306; 
p = 0.026; 
R² = 0.137
n.d. n.d. n.d. n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
myocardial fibrosis in hypertensive 
individuals
n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.308; 
p = 0.003; 
R² = 0.233
n.d. n.d. n.d. n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
age, gender, and cardiac fibrosis in 
hypertensive individuals
n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.334; 
p = 0.008; 
R² = 0.26
n.d. n.d. n.d. n.d.
p62/SQSTM1-positive BD inclusions: 
linear regression controlled for 
myocardial infarction, heart weight, 
and cardiac fibrosis in hypertensive 
individuals
n.d. n.d. n.d. n.d. n.d. n.d.
β = 0.339; 
p = 0.005; 
R² = 0.267
n.d. n.d. n.d. n.d.
Table 2. Statistical analysis: Binary logistic (*) and linear regression analysis with the frequency of p62/
SQSTM1-BD inclusions as dependent variable. The independent variables are the variables in the respective 
columns and the control variables are provided for each line. n provides the number of cases available for the 
variables in the columns used to calculate linear regression analysis. Statistical analysis of the effects on BD 
by age, gender, cardiac and AD-related pathologies and parameters, arterial hypertension, diabetes mellitus, 
atherosclerosis in the circle of Willis (CaW), cerebral small vessels disease (SVD), CAA by binary logistic (*) 
or linear regression analysis. R² reflects the degree in how far a respective model term of independent variables 
explains the dependent variable. β represents the standardized β-coefficient for each individual independent 
variable. Abbreviations: m/f Male/Female.
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myocardium was graded in 4 levels (0–3) based on the examination of Masson-Goldner stained sections: 0 = no 
fibrosis detectable, 1 = small solitary areas of fibrosis (no more than 3 areas of fibrosis in the size of no more than 
3 muscle fiber diameters), 2 = diffuse or multiple (>3 per section) areas of fibrosis, and 3 = general diffuse fibrosis 
(an area of more than 20% of the section was covered by fibrosis).
For electron microscopy formalin-fixed tissue of case No. 53 was embedded in Epon after osmium and uranyl 
acetate staining. Semi- and ultrathin sections were cut. Semithin sections were stained with methylene blue. For 
electron microscopy a JEM-1400 electron microscope (JEOL, Tokyo, JP) was used and grids were block stained 
with lead citrate.
To determine the distribution of the p62/SQSTM1-positive BD-inclusions in cardiomyocytes we embedded 
gross sections of the apex, left and right ventricle including the intraventricular septum, and both atria with 
septum intraatriale of 8 cases (cases No. 17, 21, 30, 33, 39, 44, 52, and 55) in paraffin, stained paraffin sections 
with H&E, and immunostained them with anti-p62/SQSTM1 antibodies. For semiquantitative assessment of the 
density of BD-inclusions we counted the number of p62/SQSTM1-positive inclusions in the entire myocardium 
covered in a given section from the left ventricle (all cases), the right ventricle, the atria and the intraventricular 
septum (from the 8 cases processed for paraffin macrosections of the latter 4 regions) and measured the area of 
the respective myocardial tissue with the ImageJ image analysis software (NIH, Bethesda, USA). A total area of 
1–3 cm² myocardium was assessed per case and region depending on the size of the embedded samples. These 
data were used to calculate the BD-inclusion frequency/mm2.
Neuropathologically, the degree of AD pathology30, the phase of Aβ deposition in the MTL27, the stage of 
NFT-pathology28, the CERAD-score of neuritic plaque pathology29, the expansion of atherosclerosis in the Circle 
of Willis26, and the stages of cerebral small vessel disease25 were assessed as described previously. The grade of cer-
ebral amyloid angiopathy (CAA)-related vessel wall destruction, i.e. the CAA severity, has been rated according 
to Vonsattel et al.24: 0 = no CAA; 1 = Aβ-positive material in vessel wall(s) without significant smooth muscle cell 
degeneration; 2 = Aβ-positive material in vessel wall(s) with significant destruction and fibrosis of media; and 
3 = Aβ-positive material in vessel wall(s) with micro- or macrohemorrhages.
Assessment of clinical characteristics. Clinical data were analyzed retrospectively (Suppl. Table 1). The 
clinical protocols and the autopsy reports provided information about a history of arterial hypertension, dia-
betes mellitus, hyperlipoproteinemia, obesity, coronary heart disease, myopathies, clinically evident episodes 
of embolic diseases, atrial fibrillation, anticoagulation treatment, brain disorders as well as other diseases and 
the pathologically-confirmed cause of death. Myocardial and cerebral infarction, brain pathology including 
AD-lesions and other findings were taken from the autopsy reports.
Electrocardiograms, heart ultrasound reports, heart magnetic resonance imaging, myocardial positron emis-
sion tomography and coronary angiography reports were screened in the event that these diagnostic tools were 
applied prior to death and were, in so doing, available only in a subset of the cases. The clinical diagnosis of a 
distinct heart disease was noted. Cases without clinical signs of heart disease during lifetime were considered to 
have no clinically apparent signs of heart disease (Suppl. Table 1).
Statistical analysis. Statistical analysis was carried out by using binary logistic as well as linear regression 
analysis. For binary logistic and linear regression analysis we used in the first step a model term with one depend-
ent and one independent variable. In the event that this analysis revealed a significant association we included 
further independent variables into the model term to control for, e.g. age and gender. To avoid collinearity effects 
we limited the maximum number of independent variables to four. The R²-values provided by linear regression 
analysis refer to the entire model term (including all independent variables) and give information up to which 
extend a given model term describes the dependent variable. The effects of the independent variables were pro-
vided by the respective standardized β-coefficients and p-values.
For comparing frequencies of BD-lesions among different parts of the heart (atria, left and right ventricles and 
intraventricular septum) the Wilcoxon rank sum test was used. Calculations of the statistical tests were performed 
with IBM-SPSS 24 software.
Ethics. Ethical approval by the Ulm University Ethics Committee (Decision-No. 378/13). An informed con-
sent for autopsy and scientific use of autopsy tissue with clinical information was granted for all cases included. 
All methods have been performed in accordance with the relevant guidelines and regulations.
Data Availability
All cases are listed in supplementary table with measurements obtained throughout this study, with the main 
clinical diagnosis, age and gender. Due to legislation and privacy protection any medical reports and files of the 
cases included in this study cannot be made available.
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